•
Shanghai Henlius Biotech (HKG: 2696) has announced receiving orphan drug designation (ODD) status from the European Committee for its HanSiZhuang (serplulimab) for the treatment of small-cell lung cancer (SCLC). The programmed death-1 (PD-1) inhibitor, previously awarded ODD status in the US for the same indication, is expected to become the…
•
US-based XingImaging LLC and China-based Mitro Biotech Co., Ltd have announced a partnership to provide contract research services in China. The collaboration aims to partner with global pharma and biotech companies in the target market, focusing on neuroscience and oncology. XingImaging: Specializing in Radiotracer Production and PET AcquisitionXingImaging, based in…
•
China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US major Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) to investigate Doer Bio’s anti-Claudin18.2 antibody DR30303 in combination with MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with gastric or gastroesophageal junction cancer (GC/GEJ). Under the…
•
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd has been removed from the Unverified List (UVL) by the US Department of Commerce, effective December 16, 2022. Consequently, both of WuXi Bio’s subsidiaries previously on the list have…
•
China-based Cryofocus Medtech (Shanghai) Co., Ltd, a minimally invasive interventional cryotherapy device maker, is set to make an initial public offering (IPO) of 11.11 million shares to the Hong Kong Stock Exchange, priced at HKD 18.9 (USD 2.43) per share. This amounts to an HKD 210 million (USD 27 million)…
•
The National Medical Products Administration (NMPA) has approved Chinese firms SonoScape Medical Corp’s intravascular ultrasound diagnostic equipment and Acoustic Life Science Co., Ltd’s disposable intravascular ultrasound diagnostic catheter for marketing as innovative products. The two products are used together for the ultrasonic imaging inspection of coronary artery intravascular lesions. Innovative…
•
German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA) for its Spevigo (spesolimab) to treat generalized pustular psoriasis (GPP) in adults. Notably, the drug, previously awarded breakthrough therapy and priority review statuses in China, took a mere three months after gaining approval in the…
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approval from the National Medical Products Administration (NMPA) for its intracranial PTA balloon NEO-Skater, designed to improve blood flow perfusion in atherosclerotic intracranial vessels. NEO-Skater: Innovative Design and BenefitsNEO-Skater features an improved lubrication coating on the catheter platform and…
•
China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early positive update from a Phase II trial underway for envafolimab, the Alphamab-discovered programmed death-ligand 1 (PD-L1) antibody capable of subcutaneous injection. The pivotal ENVASARC trial, being conducted by Tracon in the US and UK, is…
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part one of a Phase IIb clinical study for STP705, a therapeutic that combines TGF-β1/COX-2 with histidine-lysine polypeptide (siRNA/HKP) nanoparticle silencing. The trial is assessing the therapy as a treatment for cutaneous squamous cell carcinoma in…
•
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase I clinical trial in Australia for its independently developed HLX60 (recombinant anti-GARP humanized monoclonal antibody injection) in combination with Henlius’s innovative in-house anti-PD-1 mAb serplulimab. The trial is assessing the combination in treating general advanced…
•
China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer that will allow the former to import and distribute Pfizer’s COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) in mainland China from December 14, 2022, to November 30, 2023. No financial details were disclosed. Paxlovid: Indications and Market…
•
China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its in-house developed recyclable vena cava filter, ZYLOX Octoplus, for the prevention of pulmonary embolism (PE) caused by peripheral deep vein thrombosis (DVT). Market…
•
China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South Korea firm LG Chem Life Sciences, obtaining exclusive development and commercialization rights to the latter’s tigulixostat in China. Innovent Bio will pay LG Chem a USD 10 million upfront payment and is committed to USD…
•
Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD 15 million, co-led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund. The proceeds will be used to leverage an innovative discovery platform and advance the company’s lead drug candidates to treat…
•
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and Hong Kong Science & Technology Parks (HKSTP) announced a partnership to promote a biomedicine cultivation program in the HKSTP. No financial details were disclosed. Program Objectives and SupportThe program aims to attract the world’s top…
•
China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s oral COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) in China. The price for one box covering a single course of treatment was set at RMB 2,980 (USD 428.23). 111 later released a statement noting that the drug…
•
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with US firm ImmunoGen, Inc. (Nasdaq: IMGN). Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company, and ImmunoGen will provide…
•
UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into the companion diagnostics (CDx) field. No financial details were disclosed. Abcam’s Role in Life Science ResearchAbcam is a global life science company supporting customers at the forefront of life science research, and is engaged in…
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining global development, manufacturing, and commercialization rights to antibody conjugate drugs (ADCs) based on the latter’s ADC technology platform, focusing on two designated, undisclosed targets. No financial details were revealed. Medilink’s ADC TechnologyMedilink Therapeutics boasts the…